Mari Manuia - Concepedia

Concepedia

Author

Mari Manuia

Genomics Institute of the Novartis Research Foundation

Also Known As

M M Manuia, M. Manuia, Mari Manuia

24

Publications

1.5K

Citations

8

H-Index

26

Concepts

All Affiliations

Genomics Institute of the Novartis Research Foundation D. E. Shaw Research

MM

About

Mari Manuia is an author at Genomics Institute of the Novartis Research Foundation specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	1.2K
2	Natural Sciences	2	2	272
3	Biochemistry	2	2	272
4	Molecular Biology	2	2	272
5	Cell Biology	1	1	255

Mari Manuia

×

8

Publications

1.5K

Citations

8

H-Index

	Year	Citations
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors Yong Jia, Cai‐Hong Yun, Eunyoung Park, Nature Molecular PharmacologyMedicinePharmacologyMutant-selective Allosteric InhibitorsNovel Therapy	2016	851
Superoxide dismutase 1 (SOD1) is essential for H <sub>2</sub> O <sub>2</sub> -mediated oxidation and inactivation of phosphatases in growth factor signaling Jose C. Juarez, Mari Manuia, Mark E. Burnett, Proceedings of the National Academy of Sciences Endothelial CellsLipid PeroxidationMolecular BiologyRedox BiologyTumor Biology	2008	255
EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor Yong Jia, Jose Juarez, Jie Li, Cancer Research	2016	120
Discovery of (<i>R</i>,<i>E</i>)-<i>N</i>-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers G. Lelais, Robert Epple, Thomas H. Marsilje, Journal of Medicinal Chemistry Tumor BiologyGood Wt-egfr SelectivityNew TherapiesEgfr MutantsAnti-cancer Agent	2016	94
Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth Fernando Doñate, Graham C. Parry, Yuval Shaked, Clinical Cancer Research	2008	91
Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224) Fernando Doñate, J. Juárez, Mark E. Burnett, British Journal of Cancer	2008	76
Structure-Based Design of Selective LONP1 Inhibitors for Probing <i>In Vitro</i> Biology Laura J. Kingsley, Xiaohui He, Matthew McNeill, Journal of Medicinal Chemistry Molecular PharmacologyDrug TargetDrug TargetingBiochemistrySelective Lonp1 Inhibitors	2021	17
HTRF Kinase Assay Development and Methods in Inhibitor Characterization Yong Jia, Mari Manuia, Jose Juarez Methods in molecular biology Signaling PathwayMedicineReceptor Tyrosine KinaseInhibitor CharacterizationPharmacology	2015	12

Page 1